All news

Helus Pharma's psychedelic depression drug HLP003 succeeds in late-stage trial

Reuters (via Yahoo Finance) · · AI-summarised by FinFlash

Helus Pharma said HLP003, a modified psilocin taken alongside standard antidepressants, met its main goal in a late-stage trial of 222 adults with major depressive disorder. Patients improved 19.5 points on a depression scale after six weeks versus 11.9 on placebo, and remission reached 50.9% versus 18.2%. Three treatment-related serious adverse events were reported. US shares rose more than 20% premarket; a second study reads out in late 2027.

So What?

Positive for the psychedelic-medicine niche, but volatile trading shows investors are weighing safety and the long road to approval.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.